Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation
David J. Seiffge,Gian Marco De Marchis,Masatoshi Koga,Maurizio Paciaroni,Duncan Wilson,Manuel Cappellari,Kosmas Macha,Georgios Tsivgoulis,Gareth Ambler,Shoji Arihiro,Leo H. Bonati,Bruno Bonetti,Bernd Kallmünzer,Keith W. Muir,Paolo Bovi,Henrik Gensicke,Manabu Inoue,Stefan Schwab,Shadi Yaghi,Martin M. Brown,Philippe Lyrer,Masahito Takagi,Monica Acciarrese,Hans Rolf Jager,Alexandros A. Polymeris,Kazunori Toyoda,Michele Venti,Christopher Traenka,Hiroshi Yamagami,Andrea Alberti,Sohei Yoshimura,Valeria Caso,Stefan T. Engelter,David J. Werring,RAF‐DOAC the RAF,Kosmas Macha, MD,
DOI: https://doi.org/10.1002/ana.25700
IF: 11.2
2020-02-27
Annals of Neurology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>It is unknown whether patients with atrial fibrillation (AF) with ischaemic stroke despite oral anticoagulant therapy are at increased risk for further recurrent strokes and how ongoing secondary prevention should be managed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We conducted an individual patient data pooled analysis of seven prospective cohort studies which recruited patients with AF and cerebral ischemia. We compared patients taking oral anticoagulants (Vitamin K antagonists [VKA] or direct oral anticoagulants [DOAC]) prior to index event (OAC<sub>prior</sub>) with those without prior anticoagulation (OAC<sub>naive</sub>). We further compared those who changed the type (i.e. from VKA or DOAC, vice versa or DOAC to DOAC) of anticoagulation (OAC<sub>changed</sub>) with those who continued the same anticoagulation as secondary prevention (OAC<sub>unchanged</sub>). Time to recurrent ischaemic stroke (AIS) was analysed using multivariate competing risk Fine‐Gray models to calculate hazard ratios (HR) and 95% confidence intervals (95%CI). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>We included 5413 patients (median age 78years [IQR 71‐84years], 5136 [96.7%] had ischaemic stroke as the index event (median NIHSS‐on‐admission 6 [IQR 2‐12]). The median CHA<sub>2</sub>DS<sub>2</sub>‐Vasc score was 5 (IQR4‐6) and not different between OAC<sub>prior</sub> (n=1195) and OAC<sub>naive</sub> (n=4119, p=0.103). During 6128 patient‐years of follow‐up, 289 patients had AIS (4.7%/year, 95%CI 4.2‐5.3%). OAC<sub>prior</sub> was associated with an increased risk of AIS (HR 1.6, 95%CI 1.2‐2.3, p=0.005). OAC<sub>changed</sub> (n=307) was not associated with decreased risk of AIS (HR 1.2, 95%CI 0.7‐2.1, p=0.415) compared with OAC<sub>unchanged</sub> (n=585). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>Patients with AF who have a stroke despite oral anticoagulation once are at a higher risk for recurrent strokes despite a similar CHA<sub>2</sub>DS<sub>2</sub>‐Vasc score to those without prior oral anticoagulation. Better prevention strategies are needed for this high risk patient group. </p><p>This article is protected by copyright. All rights reserved.</p></section>
neurosciences,clinical neurology